Dear author,

Please note that changes made in the online proofing system will be added to the article before publication but are not reflected in this PDF.

We also ask that this file not be used for submitting corrections.

## <u>ARTICLE IN PRESS</u>

*Int. J. Oral Maxillofac. Surg. 2016; xxx: xxx–xxx* http://dx.doi.org/10.1016/j.ijom.2016.12.003, available online at http://www.sciencedirect.com



## Meta-Analysis Dental Implants

02

## A systematic review and metaanalysis of pre-clinical studies assessing the effect of nicotine on osseointegration

# A. Ghanem, T. Abduljabbar, Z. Akram, F. Vohra, S.V. Kellesarian, F. Javed: A systematic review and meta-analysis of pre-clinical studies assessing the effect of nicotine on osseointegration. Int. J. Oral Maxillofac. Surg. 2016; xxx: xxx-xxx. © 2016 Published by Elsevier Ltd on behalf of International Association of Oral and Maxillofacial Surgeons.

*Abstract.* Nicotine has been associated with vasoconstriction and an impaired cellular healing response. It is therefore likely that nicotine jeopardizes osseointegration. This systematic review and meta-analysis was performed to assess pre-clinical studies on the effect of nicotine on implant osseointegration. Databases were searched up to and including March 2016 for animal/non-human studies using the following Keywords: bone to implant contact; implant; nicotine; osseointegration; bone healing; and new bone formation. In total eight *in vivo* design studies were included and processed for data extraction. Five studies reported no significant influence of nicotine on healing around implants. Quantitative analysis of the effects of nicotine on the osseointegration of dental implants showed a significant difference in bone-to-implant contact between test and control subjects (Z = -2.49; P = 0.014). From the studies included in the present review; it appears that nicotine has an effect on implant osseointegration.

A. Ghanem<sup>1</sup>, T. Abduljabbar<sup>2</sup>, Z. Akram<sup>3</sup>, F. Vohra<sup>2</sup>, S. V. Kellesarian<sup>1</sup>, F. Javed<sup>1</sup>

<sup>1</sup>Department of General Dentistry, Eastman Institute for Oral Health, University of Rochester, Rochester, NY, USA; <sup>2</sup>Department of Prosthetic Dental Sciences, College of Dentistry, King Saud University, Riyadh, Saudi Arabia; <sup>3</sup>Department of Periodontology, Faculty of Dentistry, Ziauddin University, Karachi, Pakistan

Key words: bone regeneration; nicotine; implantology; osseointegration.

Accepted for publication 12 December 2016

**Q3** Osseointegration plays an important role in the overall success and survival of implants. However, a variety of risk factors such as peri-implant bone quality, bone density, poorly controlled diabetes mellitus, and osteoporosis may jeopardize the outcome of osseointegrated implants.<sup>1</sup> A major risk factor for lack of implant osseointegration that has received considerable attention is tobacco use.<sup>2–6</sup> Numerous studies have assessed the impact of tobacco smoking on peri-implant bone and implant failure.<sup>7-11</sup>

Tobacco smoke is known to contain more than 4000 potentially toxic substances, of which nicotine is reported to be the most detrimental.<sup>12</sup> At the cellular level, nicotine reduces the proliferation of red blood cells, macrophages, and fibroblasts and increases platelet adhesiveness.<sup>13</sup> Macroscopically, this affects healing and tissue perfusion due to micro clot formation in the blood vessels.<sup>13,14</sup> Nicotine also has a sympathomimetic action, stimulating epinephrine and norepinephrine release, which causes vasoconstriction and limits tissue perfusion.<sup>15</sup> Considering these effects, it is likely that nicotine impairs the healing potential at the bone–implant interface. Yamano et al. observed down-regulation of the expression of bone matrix-related genes and a decrease in bone formation around implants in rats receiving nicotine for 8 weeks compared with controls.<sup>16</sup>

0901-5027/000001+07

© 2016 Published by Elsevier Ltd on behalf of International Association of Oral and Maxillofacial Surgeons.

#### **2** *Ghanem et al.*

Similarly, Berley et al. showed decreased bone-to-implant contact (BIC) after implant placement in rats receiving nicotine compared with control rats receiving saline.<sup>17</sup> However, controversial results have also been reported from studies using animal models.<sup>17–19</sup> For instance, Soares et al. observed a decrease in bone formation around hydroxyapatite implants placed in the tibia and femurs of rats receiving nicotine compared with control rats receiving water as well as rats receiving alcohol.<sup>20</sup> Pereira et al. demonstrated that nicotine not only increases the synthesis of bone-forming enzymes, but also positively influences the growth and differentiation of osteoblasts.<sup>21</sup> In contrast, Cesar-Neto et al. recorded no difference in the bone healing around titanium implants in rats receiving and not receiving subcutaneous nicotine therapy.<sup>22</sup> On the other hand, Balatsouka et al. reported an increase in bone density from 2 weeks to 4 weeks around implants in rabbits receiving nicotine.2

There seems to be a debate over the pathophysiological influence of nicotine on BIC. Therefore, the aim of the present systematic review and meta-analysis was to assess pre-clinical studies that have evaluated the effect of nicotine on osseointegration.

#### Materials and methods

#### Focused question

The focused question addressed was the following: What is the effect of nicotine on osseointegration?

#### Eligibility criteria

The eligibility criteria were (1) original experimental studies (*in vivo* design), (2) inclusion of a control group (osseointegration around implants without nicotine administration), and (3) the intervention: effect of nicotine on osseointegration. Letters to the Editor, review articles, commentaries, case-series, and case reports were excluded.

#### Literature search protocol

Indexed databases (PubMed/Medline, EMBASE, ISI Web of Knowledge, and Google Scholar) were searched up to and including March 2016 for animal/non-human studies using the following Keywords: bone to implant contact; implant; nicotine; osseointegration; bone healing; and new bone formation. Titles and abstracts of studies identified using this




Fig. 1. PRISMA flow chart illustrating the selection of studies.

protocol were screened by . . . and checked for agreement. The full-texts of studies judged by title and abstract to be relevant were read and independently evaluated for compliance with the eligibility criteria. The reference lists of potentially relevant original articles and review articles were hand-searched to identify any studies that could have remained unidentified in the previous step. Any disagreement regarding the eligibility was resolved by discussion among the authors. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines flowchart of this process is detailed in Fig. 1.

The initial search yielded 30 studies. Twenty-two studies that did not fulfil the eligibility criteria were excluded. In total, eight original studies were included and processed for data extraction.

#### **Quality assessment**

A quality assessment of the studies included was performed in an attempt to increase the strength of the systematic review. The eight studies that were included were assessed for quality against the Critical Appraisal Skills Program (CASP) cohort study checklist.<sup>24</sup> The CASP tool uses a systematic approach based on 12 specific criteria: (1) the study issue is clearly focused; (2) the cohort is recruited in an acceptable way; (3) exposure (nicotine administration) is accurately measured; (4) outcome (osseointegration and/or new bone formation around implants) is accurately measured; (5) confounding factors are addressed; (6) follow-up is long Q4 and complete; (7) results are clear; (8) results are precise; (9) results are credible; (10) results can be applied to the local population; (11) results fit with available evidence; (12) there are important clinical implications. A response of either 'yes', 'no', or 'cannot tell', was given for each criterion. A study could have a maximum score of 12. CASP scores were used to grade the methodological quality of each study assessed in the present systematic review.

#### Quantitative analysis

In order to answer the focused question, a meta-analysis was conducted for BIC. The mean differences between the test and control groups were estimated as the effect size measures. Heterogeneity among the studies for each outcome was assessed using Q statistics and the  $I^2$  statistic. Six of the eight studies identified reported overall mean values for BIC and were subjected to meta-analysis.<sup>16,18,22,23,25,26</sup>

#### Results

Eight studies fulfilled the inclusion criteria and were included for data extraction.<sup>16–</sup> <sup>18,20,22,23,25,26</sup> Four studies were performed using rabbits<sup>18,23,25,26</sup> (three used female rabbits<sup>18,23,25</sup> and one did not report the sex of the rabbits<sup>26</sup>) and four studies were performed using male rodents.<sup>16,17,20,22</sup> In all four studies performed using rabbits, the rabbits ranged in age from 9 to 12 months.<sup>18,23,25,26</sup> The age

of the rats was reported in three studies. and ranged between 4 weeks and 9.2 weeks $^{16,17,20}$ ; one study did not report the age of the rats.<sup>22</sup> Implants were placed in the tibia in four studies,<sup>18,22,23,26</sup> in the femur in two studies, 16,17 and in both the tibia and femur in two studies.<sup>20,25</sup> The follow-up period in all studies ranged from 14 days to 90 days. Five of the studies used nicotine doses ranging from 0.37 mg/kg to 6 mg/kg.<sup>16,17,20,22,26</sup> Nicotine tartrate was used in three studies at a dose range of  $3 \,\mu g/kg/min$  to  $6 \,\mu g/kg/min$ .<sup>18,23,25</sup> The nicotine was administered by subcutaneous injection in three studies  $^{20,22,26}$  and by subcutaneously implanted mini-osmotic pump in five studies<sup>16–18,23,25</sup> (Table 1).

Titanium implants were used in seven studies<sup>16–18,22,23,25,26</sup>; one study used hydroxyapatite implants.<sup>20</sup> Seven studies did not report the number of implants used  $^{16-18,20,22,23,25}$ ; in one study, 128 were used.<sup>26</sup> All studies reported the dimensions of the implants used (diameter  $\times$  length in millimetres): the dimensions ranged between  $1 \times 2 \text{ mm}$ and  $3.75 \times 7$  mm. Five studies used rough surface titanium implants,<sup>16–18,23,25</sup> one study used both smooth surface and rough surface titanium implants,<sup>26</sup> and one study did not report the type of implant surface.<sup>22</sup> One study used dense hydroxyapatite and porous hydroxyapatite implants (Table 2).<sup>20</sup>

#### Assessment of osseointegration

The outcome variables measured in the studies were BIC, bone density in implant threads (BD-i), bone density in central bone beds without implants (BD-c), removal torque test (RMT), resonance frequency analysis (RFA), bone volume (BV), bone area (BA), resistance to load, and the expression of bone matrixrelated genes. Six studies assessed osseointegration using histomorphometric analysis.<sup>18,20,22,23,25,26</sup> Histology was used to measure new bone formation in five studies.<sup>16,18,20,23,25</sup> One study used microcomputed tomography to assess BIC.<sup>17</sup> Three studies used mechanical tests to evaluate osseointegration<sup>16,17,20</sup> and one used a quantitative reverse transcription polymerase chain reaction (QRT-PCR) to study the expression of bone matrixrelated genes.16

#### Main outcomes

Five of the studies did not observe a significant difference in BIC between the control group and the nicotine group.<sup>18,22,23,25,26</sup> Berley et al. noted a

significant decrease in BIC in the nicotine group compared with the control group at 4 weeks.<sup>17</sup> Soares et al. reported that BV in the nicotine group and nicotine + alcohol group was lower than that in the control group and alcohol group at 90 days.<sup>20</sup> The resistance to load in this study was higher in the nicotine group compared with the nicotine and alcohol group.<sup>20</sup> Yamano et al. observed comparable bone stiffness between the nicotine and control groups, and lower BIC and down-regulation of expression of bone matrix-related genes in the nicotine group compared to the control group.<sup>16</sup>

#### Quality assessment of included studies

In all studies included in the review, the total quality score ranged from 7 to 8. The study issue was focused and the participants were recruited in an acceptable way. The most common shortcomings among all studies were the short-term and incomplete follow-up of the experimental groups and the failure to address confounding factors. Furthermore, as all studies were performed in animals, caution must be practiced when applying the results to the human population. Thus, on average, the quality of these studies on the impact of nicotine on the osseointegration of implants was good; however, limitations in terms of short-term follow-up and a lack of clinical studies limit the clinical applicability of these study outcomes. The quality assessment of the individual papers is summarized in Table 3.

#### Quantitative analysis

A meta-analysis was performed for the six studies reporting mean and standard deviation values for BIC (Fig. 2).<sup>16,18,22,23,25,26</sup> Heterogeneity was found to be statistically significant for all analyses, therefore the random-effects model was employed ( $\chi^2 = 13.18$ , df = 5, P = 0.02,  $I^2 = 62\%$ ). With regard to the effect of nicotine on the osseointegration of dental implants, a significant difference was observed for BIC between the test and control subjects (Z = -2.49, P = 0.014) (Fig. 2).

#### Discussion

This study systematically reviewed the indexed literature to determine the influence of nicotine on osseointegration. It has been reported that nicotine jeopardizes bone by inhibiting neovascularization and osteoblastic differentiation.<sup>27–32</sup> Based on these findings and studies by Saito et al.<sup>27</sup> and Donigan et al.,<sup>28</sup> it

was expected that nicotine would have an adverse effect on the osseointegration of implants by promoting peri-implant inflammation. To attain the highest level of evidence, findings of both *in vivo* and *in vitro* studies were included in this systematic review.

The role of nicotine in osseointegration

Interestingly, 62.5% of the studies reviewed showed no significant influence of nicotine on healing around implants 18,22,23,25,26 It is therefore tempting to Q10 speculate that nicotine does not impair osseointegration. However, there are a number of factors that may have influenced the outcomes of these studies. Primarily, the dosage of nicotine administered varied between the studies, ranging from 0.37 mg/kg to 9 mg/kg. According to Kallala et al., high concentrations of nicotine impair BIC, while Q5 low concentrations have a stimulatory effect on bone formation around implants.<sup>33</sup> Therefore, it is difficult to estimate the minimum concentration of nicotine that would jeopardize osseointegration. Interestingly, Daffner et al., in a study on the dose-dependent effect of Q6 nicotine on bone healing, suggested that nicotine may not be responsible for the inhibited bone healing observed in smokers.<sup>34</sup> Although nicotine has been implicated as the ingredient responsible for tobacco addiction and vasoconstriction seen in smokers,<sup>35</sup> there are several other potentially toxic chemicals in tobacco smoke that could affect the bone re- Q7 sponse. Polycyclic hydrocarbons, 7,12dimethylbenz(a)anthracene, tar, and other components of cigarette smoke have been shown to compromise bone healing in smokers.<sup>36-39</sup> While the authors are by no means suggesting that nicotine may be excluded as a risk factor in bone loss around implants in smokers, it is likely that the higher implant failure rate in smokers is associated with a cascade of interactions between nicotine and other chemicals contained in tobacco smoke.7,9,40

The route of administration could be another parameter that mediates the influence of nicotine on BIC. Nicotine in these studies was provided subcutaneously to the animals, either through a pump<sup>16–18,23,25</sup> or as injections.<sup>20,22,26</sup> It is known that the absorption of a drug through the subcutaneous route is slower than the inhalational route.<sup>41</sup> Nicotine administered via inhalation (e.g. in smokers) avoids the first-pass metabolism and achieves higher serum levels in a short duration.<sup>42</sup> Therefore, it is likely that the serum nicotine profile **Q8** would be different in animals receiving subcutaneous injections compared to

3

| Author                               | Study<br>subjects<br>(n) | Mean age<br>(range), years | Study groups: (number of animals) nicotine dose   |              | of nicotine stration | Duration of study | Outcome   |  |
|--------------------------------------|--------------------------|----------------------------|---|--------------|----------------------|-------------------|---|--|
| rutior                               | (n)                      | (runge), years             | uninalis) meetine dose  | Preoperative | Postoperative        | study             |   |  |
| Nicotine delivery                    | vusing a subcut          | taneous injection          |   |              |                      |                   |   |  |
| Stefani et al.,                      | 32                       | NA                         | Control: (8) saline   | Not          | 7 days/week          | 6 weeks           | No difference among the 4 groups  |  |
| 2002 <sup>26</sup>                   | rabbits                  | (9–12 months)              | Test 1: (8) 0.37 mg/kg nicotine<br>Test 2: (8) 0.57 mg/kg nicotine<br>Test 3: (8) 0.93 mg/kg nicotine                                 | administered |                      |                   |   |  |
| Cesar-Neto                           | 45 male                  | NA (NA)                    | Control 1: (19) control   | Not          | Twice daily          | 60 days           | No difference in BIC between  |  |
| et al., 2003 <sup>22</sup>           | rats                     |                            | Control 2: (15) CIG<br>Test: (11) 3 mg/kg nicotine  | administered |                      |                   | control 1 and control 2 and test group                                  |  |
| Soares<br>et al., 2010 <sup>20</sup> | 20 male<br>rats          | 65 days<br>(NA)            | Control 1: (5) water<br>Control 2: (5) alcohol<br>Control 3: (5) alcohol +<br>1.25 mg/kg nicotine<br>Test: (5) 1.25 mg/kg<br>nicotine | 4 weeks      | veeks 90 days        |                   | BV in test group was lower than<br>control 1 and 2                      |  |
| Nicotine delivery                    | , using subcutar         | neous implanted mini-      | osmotic pump  |              |                      |                   |   |  |
| Balatsouka                           | 16                       | NA                         | Control: (8) saline   | 4 weeks and  | 2 weeks and          | 8 weeks           | No difference between control   |  |
| et al., 2005 <sup>18</sup>           | female<br>rabbits        | (9–12 months)              | Test: (8) 4.5 mg/kg nicotine tartrate   | 6 weeks      | 4 weeks              |                   | and test groups   |  |
| Balatsouka                           | 16                       | NA                         | Control: (8) saline   | 4 weeks and  | 2 weeks and          | 8 weeks           | No difference between control   |  |
| et al., 2005 <sup>23</sup>           | female<br>rabbits        | (9–12 months)              | Test: (8) 9 mg/kg<br>nicotine tartrate  | 6 weeks      | 4 weeks              |                   | and test groups   |  |
| Gotfredsen                           | 20                       | NA                         | Control: (10) saline  | 24 weeks and | 2 weeks and          | 28 weeks          | No difference between control   |  |
| et al., 2009 <sup>25</sup>           | female<br>rabbits        | (9–12 months)              | Test: (10) 9 mg/kg<br>nicotine tartrate   | 26 weeks     | 4 weeks              |                   | and test groups   |  |
| Berley et al.,                       | 30 male                  | NA                         | Control: (15) saline  | 4 weeks      | 2 weeks and          | 6 and 8 weeks     | Lower rate of BIC (implant  |  |
| 2010 <sup>17</sup>                   | rats                     | (4–6 weeks)                | Test: (15) 6 mg/kg<br>nicotine  |              | 4 weeks              |                   | push in) at 2 and 4 weeks<br>in test group compared<br>to control group |  |
| Yamano                               | 44 male                  | NA                         | Control: (22) saline  | 4 weeks      | 2 weeks and          | 6 and 8 weeks     | BIC lower in test group   |  |
| et al., 2010 <sup>16</sup>           | rats                     | (4–6 weeks) <sup>a</sup>   | Test: (22) 6 mg/kg<br>nicotine  |              | 4 weeks              |                   | compared to control   |  |

Table 1. General characteristics of the studies included.

NA, not available; CIG, intermittent cigarette smoke inhalation; BV, bone volume; BIC, bone-to-implant contact.

<sup>a</sup> Implant-free osteotomy (mock surgery) of the same size and depth as the implant dimensions created at the corresponding site in three rats.

Q19

YIJOM 3566 1-7

4

Ghanem et al.

5

#### Table 2. Characteristics of the implants included.

| Author                          | Number of implants $(n)$   | Implant dimensions (diameter $\times$ length, mm | Location<br>of implant<br>) placement |                       | Implant surface characteristics                            |
|---------------------------------|----------------------------|--|---------------------------------------|-----------------------|--|
| Stefani et al. <sup>26</sup>    | Titanium (128)             | $)3.75 \times 7$                                 | Tibia                                 | Screw                 | Group 1: 64 rough surface<br>Group 2: 64 smooth<br>surface |
| Cesar-Neto et al. <sup>2</sup>  | <sup>2</sup> Titanium (NA) | $2.2 \times 4$                                   | Tibia                                 | Screw                 | NA   |
| Balatsouka et al. <sup>13</sup> | <sup>8</sup> Titanium (NA) | $3.5 \times 6$                                   | Tibia                                 | NA                    | Rough surface  |
| Balatsouka et al. <sup>2</sup>  | <sup>3</sup> Titanium (NA) | $3.5 \times 6$                                   | Tibia                                 | NA                    | Rough surface  |
| Gotfredsen et al. <sup>2</sup>  | <sup>5</sup> Titanium (NA) | $3.5 \times 6$                                   | Tibia, femu                           | rNA                   | Rough surface  |
| Berley et al. <sup>17</sup>     | Titanium (NA)              | $1 \times 2$                                     | Femur                                 | Unthreaded cylindrica | 1Rough surface   |
| Soares et al. <sup>20</sup>     | HAP, HAD                   | $2 \times 3$                                     | Tibia, femu                           |                       | HAP 10–100 mm<br>diameter pores                            |
| Yamano et al. <sup>16</sup>     | Titanium (NA)              | $1 \times 2$                                     | Femur                                 | Unthreaded cylindrica | lRough surface   |

NA, not available; HAP, porous hydroxyapatite; HAD, dense hydroxyapatite.

Table 3. Quality assessment of studies included.<sup>a</sup>

| Author                          | Item<br>1 | Item<br>2 | Item 3 | Item<br>4 | Item<br>5 | Item<br>6 | Item<br>7 | Item<br>8 | Item<br>9 | Item<br>10 | Item 11     | Item<br>12 | Total quality score (0–12) |
|---------------------------------|-----------|-----------|--------|-----------|-----------|-----------|-----------|-----------|-----------|------------|-------------|------------|----------------------------|
| Stefani et al. <sup>26</sup>    | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Cesar-Neto et al. <sup>22</sup> | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Balatsouka et al. <sup>18</sup> | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Balatsouka et al. <sup>23</sup> | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Gotfredsen et al. <sup>25</sup> | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Berley et al. <sup>17</sup>     | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Soares et al. <sup>20</sup>     | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |
| Yamano et al. <sup>16</sup>     | Yes       | Yes       | Yes    | Yes       | No        | No        | Yes       | Yes       | Yes       | No         | Cannot tell | Yes        | 8                          |

<sup>a</sup> See Materials and methods (Quality assessment) for a description of the items.

humans with a smoking habit. Clinically, the results reported in the studies included here in terms of the bone response to subcutaneous nicotine may have limited application in smokers. However, it is hypothesized that along with the dose of nicotine, the route and frequency of administration, as well as the synergistic effect of nicotine and other chemicals, may affect the marginal bone loss around implants in individuals exposed to different concentrations of nicotine.


It is pertinent to mention that there was a marked variation in the follow-up duration of the studies. Although the duration of the studies ranged from 6 weeks to 28 weeks, the follow-up period after implant placement was 4 weeks in approximately 60% of studies included in the present systematic review.<sup>16–18,23,25,26</sup> Berglundh et al. showed that at 4 weeks the tissue regeneration around implants is mainly immature woven bone.<sup>43</sup> Healing is completed at 6 weeks to 3 months after implant placement, with the transformation of woven bone into lamellar bone.<sup>43</sup> It is hypothesized that the precise effects of nicotine around implants would require long-term

follow-up after implant placement. From a clinical perspective, the duration of a nicotine habit, daily frequency of nicotine consumption, and the patient's oral hygiene status may all be interrelated to cause an effect of bone loss.

011

The timing of nicotine administration (pre and/or post implant placement) is another parameter that could influence BIC. Two studies administered nicotine only after implant placement,<sup>22,26</sup> while in the remaining six studies, nicotine was administered in both the pre-surgical and post-surgical period.<sup>16–18,20,23,25</sup>

| Study                                      | Test  |      |       | Control |                  |                      | Mean Difference<br>IV, Random, 95% |                            |
|--|-------|------|-------|---------|------------------|----------------------|------------------------------------|----------------------------|
|  | Mean  | SD   | Total | Mean    | SD               | Total                | CI                                 |                            |
| Yamano et al. <sup>15</sup>                | 59.4  | 13   | 22    | 70.9    | 9.2              | 22                   | -1.00 [-1.64, -0.36]               | <b>_</b> _                 |
| Balatsouka et al. <sup>17</sup>            | 51.3  | 6.7  | 8     | 57.6    | 6.9              | 8                    | -0.87 [-1.94, 0.19]                |                            |
| Cesar-Nato et al. <sup>21</sup>            | 33.13 | 8.87 | 11    | 32.99   | 10.3             | 34                   | -0.01 [-0.67, 0.70]                |                            |
| Balatsouka et al. <sup>22</sup>            | 51.7  | 15.3 | 8     | 49.6    | 8.7              | 8                    | 0.16 [-0.85, 1.17]                 |                            |
| Gotfredsen et al. <sup>24</sup>            | 44.5  | 10.9 | 10    | 52.3    | 8.6              | 10                   | -0.75 [-1.69, 0.17]                |                            |
| Stefanie et al. <sup>25</sup>              | 45.54 | 3.06 | 24    | 55.6    | 11               | 8                    | -1.64 [-2.56, -0.73]               |                            |
| Total                                      |       |      | 83    |         |                  | 90                   | -0.67 [-1.21, -0.14]               |                            |
| Test for heterogen<br>Test for overall eff |       |      |       |         | 0 <b>.02);</b> ] | l <sup>2</sup> = 62% |                                    | -3 <u>-2</u> -1 0 1 2      |
| - could of the ch                          |       | ,    |       | .,      |                  |                      |                                    | Favors Test Favors Control |



## <u>ARTICLE IN PRESS</u>

#### **6** *Ghanem et al.*

Again the duration of nicotine administration did not exceed 4 weeks in most studies.<sup>16–18,23,25,26</sup> Hollinger et al. showed that the adverse effects of nicotine on bone healing were more severe in the late healing period than immediately after surgery.<sup>44</sup> It is possible that, in the early healing phase, sufficient concentrations of endogenous cells and signalling factors promote bone formation regardless of the presence of nicotine. It has been suggested that when bone regeneration exhausts the local supply of growth factors and cells, an adequate blood supply to the healing site would be needed for their replenishment.44 It has also been suggested that nicotine causes peripheral vasoconstriction<sup>45</sup> and down-regulates osteoblastic activity,<sup>46–48</sup> which could contribute to implant failure in humans. Perhaps if these studies had used longer durations of nicotine supplementation, possibly 6 weeks or greater, there may have been some difference in the BIC between the study and control animals.<sup>18,22,23,25,26</sup>

The implants in the studies included were placed in dense cortical bone (tibia and femur) of the animals. The mandible has more cortical bone compared to the maxilla, which has more trabecular bone.<sup>49</sup> It is reasoned that BIC would be greater in dense cortical bone than in trabecular bone. Jaffin and Berman showed significantly lower success rates for implants placed in bones with a thin cortex and poorer medullary strength compared to implants placed in dense cortical bone.<sup>49</sup> Therefore, the results of these studies have questionable application to implants placed in the oral cavity, where, not only the difference in bone quality within the maxilla and mandible, but also the effect of local factors such as oral hygiene status, may influence osseointegration. Hence, from a clinical standpoint the outcomes of these studies should be interpreted with caution.

From the studies included in the present review, it appears that nicotine has an effect on implant osseointegration. From a clinical perspective, the detrimental effects of tobacco smoking (which results in the intake of a variety of toxic components) on osseointegration cannot be disregarded.

#### Funding

The authors extend their sincere apprecia- **Q12** tion to the Deanship of Scientific Research at King Saud University for its funding of this prolific research group (PRG-1437-38).

#### **Competing interests**

None declared.

#### Ethical approval

Not applicable.

#### Patient consent

Not applicable.

#### References

- Neukam FW, Flemmig TF. Local and systemic conditions potentially compromising osseointegration. Consensus report of Working Group 3. *Clin Oral Implants Res* 2006;17(Suppl. 2):160–2.
- Lindquist LW, Carlsson GE, Jemt T. Association between marginal bone loss around osseointegrated mandibular implants and smoking habits: a 10-year follow-up study. *J Dent Res* 1997;**76**:1667–74.
- Schwartz-Arad D, Samet N, Samet N, Mamlider A. Smoking and complications of endosseous dental implants. *J Periodontol* 2002;**73**:153–7.
- Weyant RJ. Characteristics associated with the loss and peri-implant tissue health of endosseous dental implants. *Int J Oral Maxillofac Implants* 1994;9:95–102.
- McDermott NE, Chuang SK, Woo VV, Dodson TB. Complications of dental implants: identification, frequency, and associated risk factors. *Int J Oral Maxillofac Implants* 2003;18:848–55.
- 6. Al Amri MD, Kellesarian SV, Abduljabbar TS, Al-Rifaiy MQ, Al Baker AM, Al-Keraif AA. Comparison of peri-implant soft tissue parameters and crestal bone loss around immediately-loaded and delayed loaded implants among smokers and nonsmokers: 5-year follow-up results. J Periodontol 2016:1–12.
- 7. Turri A, Rossetti PH, Canullo L, Grusovin MG, Dahlin C. Prevalence of peri-implantitis in medically compromised patients and smokers: a systematic review. *Int J Oral Maxillofac Implants* 2016;**31**:111–8.
- Moraschini V, Barboza E. Success of dental implants in smokers and non-smokers: a systematic review and meta-analysis. *Int J Oral Maxillofac Surg* 2016;45:205–15.
- Manzano G, Montero J, Martin-Vallejo J, Del Fabbro M, Bravo M, Testori T. Risk factors in early implant failure: a meta-analysis. *Implant Dent* 2016;25:272–80.
- Keenan JR, Veitz-Keenan A. The impact of smoking on failure rates, postoperative infection and marginal bone loss of dental implants. *Evid Based Dent* 2016;17:4–5.
- Chrcanovic BR, Albrektsson T, Wennerberg A. Smoking and dental implants: a systematic review and meta-analysis. *J Dent* 2015;43:487–98.

- Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health 1997;50:307–64.
- Sherwin MA, Gastwirth CM. Detrimental effects of cigarette smoking on lower extremity wound healing. J Foot Surg 1990;29:84–7.
- Mosely LH, Finseth F. Cigarette smoking: impairment of digital blood flow and wound healing in the hand. *Hand* 1977;9:97–101.
- Jones JK, Triplett RG. The relationship of cigarette smoking to impaired intraoral wound healing: a review of evidence and implications for patient care. *J Oral Maxillofac Surg* 1992;**50**:237–9. discussion 239–40.
- Yamano S, Berley JA, Kuo WP, Gallucci GO, Weber HP, Sukotjo C. Effects of nicotine on gene expression and osseointegration in rats. *Clin Oral Implants Res* 2010;**21**:1353–9.
- Berley J, Yamano S, Sukotjo C. The effect of systemic nicotine on osseointegration of titanium implants in the rat femur. *J Oral Implantol* 2010;**36**:185–93.
- Balatsouka D, Gotfredsen K, Lindh CH, Berglundh T. The impact of nicotine on bone healing and osseointegration. *Clin Oral Implants Res* 2005;16:268–76.
- Nociti Jr FH, Stefani CM, Sallum EA, Duarte PM, Sallum AW. Nicotine and bone density around titanium implants: a histometric study in rabbits. *Implant Dent* 2002;11:176–82.
- Soares EV, Favaro WJ, Cagnon VH, Bertran CA, Camilli JA. Effects of alcohol and nicotine on the mechanical resistance of bone and bone neoformation around hydroxyapatite implants. *J Bone Miner Metab* 2010;28: 101–7.
- Pereira ML, Carvalho JC, Peres F, Gutierres M, Fernandes MH. Behaviour of human osteoblastic cells cultured on plasmasprayed titanium implants in the presence of nicotine. *Clin Oral Implants Res* 2008;19:582–9.
- 22. Cesar-Neto JB, Duarte PM, Sallum EA, Q13 Barbieri D, Moreno Jr H, Nociti Jr FH. A comparative study on the effect of nicotine administration and cigarette smoke inhalation on bone healing around titanium implants. *J Periodontol* 2003;**74**:1454–9.
- 23. Balatsouka D, Gotfredsen K, Lindh CH, Berglundh T. The impact of nicotine on osseointegration. An experimental study in the femur and tibia of rabbits. *Clin Oral Implants Res* 2005;**16**:389–95.
- 24. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools Q14 for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8:2–10.
- 25. Gotfredsen K, Lindh CH, Berglundh T. Does longstanding nicotine exposure impair bone healing and osseointegration? An experimental study in rabbits. J Biomed Mater Res B: Appl Biomater 2009;91:918–23.

#### *The role of nicotine in osseointegration* **7**

- 26. Stefani CM, Nogueira F, Sallum EA, de TS, Sallum AW, Nociti Jr FH. Influence of nicotine administration on different implant surfaces: a histometric study in rabbits. JPeriodontol 2002;73:206–12.
  - Saito Y, Sato S, Oginuma T, Saito Y, Arai Y, Ito K. Effects of nicotine on guided bone augmentation in rat calvarium. *Clin Oral Implants Res* 2013;24:531–5.
  - Donigan JA, Fredericks DC, Nepola JV, Smucker JD. The effect of transdermal nicotine on fracture healing in a rabbit model. *JOrthop Trauma* 2012;26:724–7.
  - Theiss SM, Boden SD, Hair G, Titus L, Morone MA, Ugbo J. The effect of nicotine on gene expression during spine fusion. *Spine* 2000;25:2588–94.
  - Zheng LW, Ma L, Cheung LK. Changes in blood perfusion and bone healing induced by nicotine during distraction osteogenesis. *Bone* 2008;43:355–61.
  - Ma L, Zheng LW, Cheung LK. Inhibitory effect of nicotine on bone regeneration in mandibular distraction osteogenesis. *Front Biosci* 2007;12:3256–62.
  - Glowacki J, Schulten AJ, Perrott D, Kaban LB. Nicotine impairs distraction osteogenesis in the rat mandible. *Int J Oral Maxillofac Surg* 2008;37:156–61.
  - Kallala R, Barrow J, Graham SM, Kanakaris N, Giannoudis PV. The in vitro and in vivo effects of nicotine on bone, bone cells and fracture repair. *Expert Opin Drug Saf* 2013;12:209–33.
  - 34. Daffner SD, Waugh S, Norman TL, Mukherjee N, France JC. Nicotine increases osteoblast activity of induced bone marrow stromal cells in a dose-dependent manner: an in vitro cell culture experiment. *Glob Spine J* 2012;2:153–8.

- Ciftci O, Gunday M, Caliskan M, Gullu H, Guven A, Muderrisoglu H. Light cigarette smoking and vascular function. *Acta Cardiol* 2013;68:255–61.
- 36. Iqbal J, Sun L, Cao J, et al. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. *Proc Natl Acad Sci U S A* 2013;**110**:11115–20.
- Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration. *Biochem Pharmacol* 2005;**70**:300–7.
- Jamsa T, Viluksela M, Tuomisto JT, Tuomisto J, Tuukkanen J. Effects of 2,3,7,8tetrachlorodibenzo-p-dioxin on bone in two rat strains with different aryl hydrocarbon receptor structures. *J Bone Miner Res* 2001;**16**:1812–20.
- Voronov I, Li K, Tenenbaum HC, Manolson MF. Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB. *Biochem Pharmacol* 2008;**75**:2034–44.
- Ferreira CF, Buttendorf AR, de Souza JG, Dalago H, Guenther SF, Bianchini MA. Prevalence of peri-implant diseases: analyses of associated factors. *Eur J Prosthodont Restor Dent* 2015;23:199–206.
- Romich JA. Fundamentals of pharmacology for veterinary technicians. Thomson Delmar Learning; 2005.
- DeSimone E, Scott D. Nicotine and caffeine abuse. *Applied therapeutics: the clinical use* of drugs. 5th ed. Vancouver: Applied Therapeutics, Inc.; 1992: 85–113.
- 43. Berglundh T, Abrahamsson I, Lang NP, Lindhe J. De novo alveolar bone formation

adjacent to endosseous implants. *Clin Oral Implants Res* 2003;**14**:251–62.

- Hollinger JO, Schmitt JM, Hwang K, Soleymani P, Buck D. Impact of nicotine on bone healing. *J Biomed Mater Res* 1999;45:294– 301.
- 45. Daftari TK, Whitesides Jr TE, Heller JG, Goodrich AC, McCarey BE, Hutton WC. Nicotine on the revascularization of bone graft. An experimental study in rabbits. *Spine* 1994;19:904–11.
- 46. Fang MA, Frost PJ, Iida-Klein A, Hahn TJ. Effects of nicotine on cellular function in UMR 106-01 osteoblast-like cells. *Bone* 1991;12:283–6.
- Payne JB, Johnson GK, Reinhardt RA, Dyer JK, Maze CA, Dunning DG. Nicotine effects on PGE2 and IL-1 beta release by LPStreated human monocytes. *J Periodontal Res* 1996;**31**:99–104.
- Ramp WK, Lenz LG, Galvin RJ. Nicotine inhibits collagen synthesis and alkaline phosphatase activity, but stimulates DNA synthesis in osteoblast-like cells. *Proc Soc Exp Biol Med* 1991;197:36–43.
- Jaffin RA, Berman CL. The excessive loss of Brånemark fixtures in type IV bone: a 5-year analysis. J Periodontol 1991;62:2–4.

#### Address:

Alexis Ghanem Department of General Dentistry Eastman Institute for Oral Health University of Rochester Rochester NY 14620 USA Tel: +1 585 273 1955 E-mail: Alexis\_Ghanem@urmc.rochester.edu

Q16